-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
In Brief for February 11, 2026
Nogapendekin alfa combination gains accelerated approval in Saudi Arabia for metastatic NSCLC.
-
National Report Shows Rising Lung Cancer Survival Rates but Gaps in Early Detection
The ALA’s 2025 State of Lung Cancer report highlights survival gains while revealing persistent disparities in diagnosis, treatment, and access to biomarker testing.
-
Lung Cancer is Treatable When Found Early. So Why Don’t We Screen Everyone?
Advocate and survivor Jan Pezarro details how investing in a universal age-based lung cancer screening model can save both lives and health care costs.
-
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
-
Stereotactic Radiosurgery for Established Brain Metastases: Prospective Evidence
In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.
-
Modern Brain Radiotherapy in SCLC: Integrating Hippocampal Avoidance and Stereotactic Precision
Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.
-
A Comprehensive Framework: Integrating Smoking Cessation into LCS
Experts outline how Poland aims to reduce lung cancer mortality while addressing one of the nation’s most persistent health challenges: tobacco dependence.
-
The Importance of Compassion and Clear Communication: A Patient Advocate Perspective
Patient advocate Kate Sinclair shares why communication is one of the most important tools for improving the patient experience during their lung cancer journey.
-
In Brief for January 14, 2026
The US FDA grants special designation to risvutatug rezetecan for SCLC and approves the subcutaneous formulation of amivantamab plus hyaluronidase-lpuj for EGFR+ NSCLC.